Navigation Links
iBio Obtains New IP Protection in China
Date:5/29/2013

NEWARK, Del., May 29, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary iBioModulator fusion protein technology has been allowed in China. The patent, which will issue from Chinese patent application No.: 200780008098.3, will further broaden the territories in which patent exclusivity has been secured for this novel technology.  In the U.S., the technology is covered by issued U.S. Patent 8,124,103, entitled "Influenza Antigen, Vaccine Compositions, and Related Methods."

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

"China, by virtue of the scale of its rapidly-emerging domestic market and need for new biopharmaceutical technology infrastructure to address influenza and other emerging infectious disease threats, is a target market for us," said Robert Erwin , President of iBio.  "This new intellectual property protection will further facilitate our ability to license our technology for the Chinese market."

The vaccine industry is increasingly focused on the development of recombinant vaccines instead of attenuated, live virus vaccines. These recombinant vaccines commonly require use of components called adjuvants to improve their efficacy. Lichenase protein, when fused to antigens through the use of the iBioModulator technology, acts as an adjuvant and can enhance duration of an immune response, improve production economies and increase product stability in comparison to conventional adjuvant-antigen combinations. Previously published data demonstrated significant improvement in candidate vaccine efficacy in animal models when iBioModulator technology was employed with a range of target antigens, including antigens from plague, malaria, and human papilloma virus.

The iBioModulator platform has been shown to significantly modify the immune response to a vaccine in two important ways. It increases the strength of the initial immune response to a vaccine antigen (as measured by antibody titer). It also extends the duration of the immune response. These results demonstrate that the use of the iBioModulator platform can lower vaccine antigen requirements and enable fewer doses to establish prolonged immunity. The ability to provide better immune responses and longer-term protection without booster inoculations adds significant value to a vaccine, particularly for use in a market such as China, by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform.  The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.  The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products with both higher potency and greater duration of effect.  The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Contacts

Robert Erwin ,
President
302-355-2335
rerwin@ibioinc.com       


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
2. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
3. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
4. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
5. Andrew Technologies Obtains Patent for Visceral Lipectomy Application from USPTO
6. BioElectronics Obtains Additional US Patent For Its Unique Pain Devices
7. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. Broad Patent Protection Granted for iBio Immunomodulator
10. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
11. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... the necessity of health literacy within the technology advancement of diagnostic imaging. According to a ... majority of oncology patients undergo imaging screenings without understanding the nuanced risks associated with ... ... ... Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
(Date:5/27/2016)... According to the 2016 report, ... ambulatory blood pressure monitoring system market growth. With aging, ... to respond to different pressure rates, leading to hypertension ... various cardiovascular disorders such as heart failure, stroke, coronary ... growing in prevalence each year. WHO estimates that 17 ...
Breaking Medicine Technology:
(Date:5/28/2016)... Aliso Viejo, California (PRWEB) , ... May 28, 2016 , ... ... just need to drag and drop a preset onto their media," said Christina Austin ... from Pixel Film Studios, editors can quickly and easily add stylish color grades to ...
(Date:5/27/2016)... ... 27, 2016 , ... Southland Log Homes , designer and manufacturer of ... kits, which can be found on its website at SouthlandLogHomes.com. , The designs of ... they highlight the craftsmanship of timber post and beam construction. The result is ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
Breaking Medicine News(10 mins):